Semaglutide for Women: Hormones, PCOS, and What's Different About Weight Loss on GLP-1

GLP-1 medications were initially studied predominantly in male populations and patients with type 2 diabetes. The landmark SURMOUNT and STEP trials included women, but the experience of female patients — with hormone cycles, PCOS, contraception interactions, and different metabolic profiles — is only now getting the focused attention it deserves.

The core mechanism of semaglutide and tirzepatide works the same regardless of sex. The nuances are in the layers around it: how hormones affect GLP-1 response, what PCOS changes about the clinical picture, and practical considerations unique to women.

Do GLP-1 Medications Work the Same Way in Women?

Mechanistically yes — same receptors, same appetite suppression, same metabolic effects. The clinical trial data suggests weight loss outcomes are broadly similar between men and women, though with some variation.

The STEP 1 trial (semaglutide 2.4mg) showed average weight loss of ~15% in mixed-sex populations. Subgroup analyses suggest women may see slightly greater absolute weight loss in some studies, while men may respond more quickly initially due to differences in body composition and metabolic rate.

Neither sex has a dramatically superior response. Both experience meaningful weight loss with appropriate treatment.

Hormonal Cycles and GLP-1 Response

Estrogen and progesterone affect GLP-1 receptor sensitivity, appetite regulation, and metabolic rate — and these change significantly across the menstrual cycle.

Luteal phase (post-ovulation): Progesterone rises, which increases appetite and caloric intake. Many women notice the "food noise" that GLP-1 reduces is louder in the luteal phase — the medication's appetite suppression may feel less effective in the 2 weeks before menstruation. This is a real physiological phenomenon, not failure of the medication.

Follicular phase (pre-ovulation): Estrogen-dominant phase with lower natural appetite. GLP-1's appetite suppression may feel stronger.

Practically: don't evaluate GLP-1 response by a single week. Assess over full cycles. And if side effects feel worse at certain cycle phases, tracking your symptoms against your cycle can reveal patterns that help with management.

Menstrual changes on GLP-1: Some women report changes in their menstrual cycle after starting GLP-1 medications — particularly if significant weight loss occurs. Rapid weight loss can temporarily disrupt cycles. This is typically reversible and not a cause for concern, but worth monitoring and discussing with your physician if it persists.

GLP-1 and PCOS: A Particularly Interesting Intersection

Polycystic ovary syndrome affects approximately 10–13% of women of reproductive age. It's characterized by insulin resistance, elevated androgens, irregular menstrual cycles, and often (though not always) excess body weight — particularly central adiposity.

The insulin resistance in PCOS and the insulin-sensitizing effects of GLP-1 medications overlap in a clinically meaningful way.

Weight loss improves PCOS symptoms. This is well-established. Even modest weight loss (5–10% of body weight) in women with PCOS improves menstrual regularity, reduces androgen levels, and can restore ovulation in previously anovulatory women. GLP-1's weight loss mechanism is relevant here.

GLP-1 directly improves insulin resistance. Beyond weight loss, GLP-1 receptor agonists improve insulin sensitivity directly. In PCOS, where insulin resistance drives much of the hormonal dysregulation (high insulin → high androgen production → disrupted cycle), reducing insulin resistance addresses the root cause.

Emerging data on GLP-1 specifically for PCOS: Several studies have examined semaglutide and liraglutide in PCOS populations. Results consistently show improvements in weight, insulin sensitivity, androgen levels, and menstrual regularity — often beyond what's expected from weight loss alone.

Combination with metformin: Many women with PCOS are already on metformin (another insulin sensitizer). GLP-1 medications and metformin are often used together — they have complementary mechanisms and the combination is well-tolerated.

Fertility implications for PCOS: Women with PCOS who want to conceive often struggle due to irregular ovulation. Weight loss via GLP-1 and improved insulin sensitivity can restore regular ovulatory cycles. However — critically — GLP-1 medications should be discontinued before trying to conceive and are contraindicated in pregnancy. This timing needs to be discussed with your physician.

Contraception Interactions

Oral contraceptives may have slightly altered absorption with GLP-1 medications due to delayed gastric emptying. GLP-1 slows the rate at which the stomach empties into the small intestine, where oral medications are primarily absorbed. This could theoretically reduce peak drug concentrations.

The clinical significance for contraceptive efficacy is debated — most providers do not advise switching birth control methods solely because of GLP-1. However, the FDA label for oral semaglutide (Rybelsus) specifically notes this interaction. Injectable semaglutide (Ozempic, Wegovy) has a weaker effect on gastric emptying and a less prominent interaction.

If you're on oral contraceptives and starting GLP-1 treatment, this is worth mentioning to your physician. For women where pregnancy would be particularly problematic, adding a backup contraceptive method during dose escalation (when gastric emptying effects are strongest) is a reasonable precaution.

GLP-1 and pregnancy: Contraindicated. If you're actively trying to conceive or become pregnant while on GLP-1 medication, stop the medication. The safety profile in pregnancy hasn't been established, and animal studies showed fetal abnormalities at high doses. Discontinue at least 2 months before attempting conception (longer washout is sometimes advised for injectable formulations).

Side Effects in Women: Any Differences?

GLP-1 side effects are broadly similar by sex, but women do report higher rates of nausea in some studies. The reasons are likely multifactorial: hormonal influences on gut motility and GI sensitivity, different baseline rates of GI conditions in women, and potentially differences in reporting.

Bone density: Rapid weight loss can reduce bone mineral density. Women, who already face higher lifetime osteoporosis risk than men, should be aware of this. Adequate calcium and vitamin D intake, and continued weight-bearing exercise during GLP-1 treatment, are important. Women with pre-existing osteopenia or osteoporosis should discuss bone health monitoring with their physician.

Hair loss: Telogen effluvium (stress-related hair shedding) affects both sexes but may be particularly distressing for women. Adequate protein intake — minimum 100g daily — is the primary protective factor. The shedding typically resolves within 3–6 months and doesn't result in permanent hair loss.

GLP-1 Use in Perimenopause and Menopause

The perimenopause and menopause transition involves declining estrogen, shifting body fat distribution toward central/visceral accumulation, and reduced metabolic rate. Many women experience weight gain in this period despite no significant changes in eating or activity — a hormonally driven change.

GLP-1 medications are effective in postmenopausal women. The STEP 1 trial included postmenopausal women and showed strong weight loss outcomes. The combination of GLP-1's appetite suppression and metabolic effects with hormone replacement therapy (HRT) in women who are candidates for it is an emerging area of clinical interest — both address different aspects of menopausal metabolic change.

Practical Guidance for Women Starting GLP-1

1. Track symptoms across your cycle. Understanding how your cycle phase affects side effects and efficacy helps you calibrate expectations and not over-interpret week-to-week variation.

1. Prioritize protein. At minimum 100g daily. This protects against muscle loss and telogen effluvium — both meaningful concerns.

1. If you have PCOS, tell your physician. The clinical approach and monitoring should reflect this.

1. Discuss contraception. Make sure your birth control is accounting for GLP-1's effects on gastric emptying, and have a clear plan for discontinuation if pregnancy is desired.

1. Monitor bone health if relevant. Especially for women with osteoporosis risk or in menopause.

GLP-1 medications are among the most effective interventions for obesity and metabolic disease in women. The nuances around hormones, PCOS, and contraception are manageable — they just require an informed conversation with your physician rather than a generic protocol.

Marrow's intake process is designed to surface these nuances so your treatment plan is built for your actual biology, not an average.